Funding round-up: Cellaïon, Ferronova, AI Medical Technology, Vedi, DeuterOncology

Belgium: DeuterOncology, a clinical-stage drug development company, has closed its €5.65m (US$6.1m) Series A financing, with participation from existing investor Newton Biocapital and new investors Noshaq and Investsud Tech. Funding will enable the company to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as…

You must be a HMI Subscriber to view this content.

Subscribe Now »